Suppr超能文献

水蒸气热疗法治疗良性前列腺增生较大(≥80克)所致下尿路症状

Water vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g).

作者信息

Agüero Christopher, Depaquit Thibaut Long, Uleri Alessandro, Berchiche William, Corral Renaud, Peyrottes Arthur, Bastide Cyrille, Fourmarier Marc, Baboudjian Michael

机构信息

Department of Urology, HIA Sainte-Anne, Toulon, France.

Department of Urology, AP-HM, North Hospital, Marseille, France.

出版信息

World J Urol. 2025 Jan 13;43(1):69. doi: 10.1007/s00345-024-05433-z.

Abstract

INTRODUCTION

Water vapor thermal therapy (WVTT; REZUM™; Boston, USA) offers symptom relief with reduced risks of complications in patients with lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). WVTT therapy has been validated in the pivotal study in men with smaller prostates (< 80 cc). Yet, its feasibility for larger prostates (≥ 80 cc) remains underexplored.

METHODS

This retrospective study assessed WVTT efficacy and safety in 131 patients with symptomatic BPH treated between January 2022 and March 2024. Patients were categorized based on prostate size: smaller prostates (SP) (< 80 cc) and larger prostates (LP) (≥ 80 cc). Baseline characteristics, treatment specifics, and post-procedure outcomes-including retreatment rates, symptom scores, and adverse events (AEs)-were recorded. All patients who required surgical retreatment underwent Holmium laser enucleation of the prostate (HoLEP). Statistical analyses compared results between groups over 6- and 12-month follow-up periods.

RESULTS

Among the 131 patients, 48 (37%) had LP, with a median volume of 93 cc (Interquartile range (IQR) 88-110). Patients with LP experienced more non-serious AEs, primarily hematuria (p = 0.001), although serious AEs were similar across groups and limited to urinary retention (p = 0.35). At 6 months postoperatively, LP patients had a higher PVR (42 mL(IQR 21-75) vs. 21 mL (IQR2-40); p = 0.032), though this resolved by 12 months. No significant differences were observed between the groups in IPSS, maximum flow rate (Qmax), or erectile function (IIEF-5) scores at either follow-up point. Medical retreatment rates at 12 months were similar (LP: 4% vs. SP: 7%; p = 0.39), as were surgical retreatment rates (LP: 2% vs. SP: 2%; p = 0.51). Ejaculatory function was largely preserved in both groups (LP: 96%, SP: 95%).

CONCLUSION

WVTT therapy in LP is associated with a higher risk of minor post-operative AEs, with similar functional outcomes at one year compared to SP. Longer follow-up studies are needed to compare the durability of treatment in LP.

摘要

引言

水蒸气热疗法(WVTT;REZUM™;美国波士顿)可缓解与良性前列腺梗阻(BPO)相关的下尿路症状(LUTS)患者的症状,并降低并发症风险。WVTT疗法已在前列腺较小(<80cc)男性的关键研究中得到验证。然而,其在较大前列腺(≥80cc)中的可行性仍未得到充分探索。

方法

这项回顾性研究评估了2022年1月至2024年3月期间接受治疗的131例有症状良性前列腺增生(BPH)患者的WVTT疗效和安全性。患者根据前列腺大小分类:较小前列腺(SP)(<80cc)和较大前列腺(LP)(≥80cc)。记录基线特征、治疗细节和术后结果,包括再次治疗率、症状评分和不良事件(AE)。所有需要手术再次治疗的患者均接受了钬激光前列腺剜除术(HoLEP)。统计分析比较了6个月和12个月随访期内两组的结果。

结果

在131例患者中,48例(37%)患有LP,中位体积为93cc(四分位间距(IQR)88 - 110)。LP患者经历了更多非严重AE,主要是血尿(p = 0.001),尽管严重AE在各组之间相似,且仅限于尿潴留(p = 0.35)。术后6个月,LP患者的残余尿量(PVR)较高(42mL(IQR 21 - 75)对21mL(IQR2 - 40);p = 0.032),但在12个月时恢复正常。在两个随访点,两组在国际前列腺症状评分(IPSS)、最大尿流率(Qmax)或勃起功能(IIEF - 5)评分方面均未观察到显著差异。12个月时的药物再次治疗率相似(LP:4%对SP:7%;p = 0.39),手术再次治疗率也相似(LP:2%对SP:2%;p = 0.51)。两组的射精功能在很大程度上得以保留(LP:96%,SP:95%)。

结论

LP患者的WVTT治疗术后轻微AE风险较高,与SP患者相比,一年时功能结果相似。需要更长时间的随访研究来比较LP患者治疗的持久性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验